Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Wohl

Showing results (161-170 of 185) with videos related to

Pageof 19
Sort By:
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Health and economic impacts of Lassa vaccination campaigns in West AfricaDavid R M Smith, Joanne Turner, Patrick Fahr, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Plos One|December 8, 2022
Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical centerHeather B Root, Matt Gilleskie, Chih-Huan Lu, et al.
The Journal of Infectious Diseases|May 27, 2024
Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean CohortNell G Bond, Kayla R Shore, Emily J Engel, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish Choudhary, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 studyEvelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Pageof 19

Showing results (161-170 of 185) with videos related to

Sort By:
Pageof 19
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Health and economic impacts of Lassa vaccination campaigns in West AfricaDavid R M Smith, Joanne Turner, Patrick Fahr, et al.
Medrxiv : the Preprint Server for Health Sciences|January 4, 2022
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical TrialKara W Chew, Carlee Moser, Eric S Daar, et al.
AIDS (London, England)|April 2, 2019
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trialsSamir K Gupta, Frank A Post, José R Arribas, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Plos One|December 8, 2022
Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical centerHeather B Root, Matt Gilleskie, Chih-Huan Lu, et al.
The Journal of Infectious Diseases|May 27, 2024
Ebola Virus-Specific Neutralizing Antibody Persists at High Levels in Survivors 2 Years After Resolution of Disease in a Sierra Leonean CohortNell G Bond, Kayla R Shore, Emily J Engel, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infectionJulie Boucau, Kara W Chew, Manish Choudhary, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 studyEvelyn Kung, Rinki Deo, Manish C Choudhary, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Pageof 19